CXCL12 and plasma cell myeloma: Targeting the CXCR4/CXCL12 axis with [177Lu]Lu-Pentixather, a lutetium-177-labeled CXCL12-analogue, has demonstrated promising therapeutic efficacy in a limited group of patients with hematological malignancies, including multiple myeloma and lymphomas 101.